TY  - BOOK
AU  - Grunwald,Peter
TI  - Pharmaceutical biocatalysis: important emzymes, novel targets, and therapies 
T2  - Jenny Stanford series on biocatalysis
SN  - 9781003045410
AV  - TP248.E5 P53 2021
U1  - 660.634 23
PY  - 2021///]
CY  - Singapore
PB  - Jenny Stanford Publishing
KW  - Enzymes
KW  - Industrial applications
KW  - Biocatalysis
KW  - Pharmaceutical chemistry
KW  - MEDICAL / Pharmacy
KW  - bisacsh
KW  - SCIENCE / Biotechnology
KW  - SCIENCE / Chemistry / General
N2  - This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, -Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy
UR  - https://www.taylorfrancis.com/books/9781003045397
UR  - https://www.taylorfrancis.com/books/9781003045410
UR  - http://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf
ER  -